{"name":"Human Genome Sciences Inc.","slug":"human-genome-sciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1100000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Lymphostat B","genericName":"BELIMUMAB","slug":"belimumab","revenue":1100000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2011-01-01","label":"Lymphostat B first approved","drug":"Lymphostat B","drugSlug":"belimumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":1100000000,"percentOfTotal":100,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Lymphostat B","genericName":"BELIMUMAB","slug":"belimumab","indication":"Systemic lupus erythematosus","status":"marketed","revenue":1100000000},{"name":"Belimumab plus Early Vaccination","genericName":"Belimumab plus Early Vaccination","slug":"belimumab-plus-early-vaccination","indication":"Systemic lupus erythematosus (SLE) with early vaccination strategy","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Albuferon","genericName":"Albuferon","slug":"albuferon","indication":"Other","status":"phase_2"},{"name":"Belimumab plus Late Vaccination","genericName":"Belimumab plus Late Vaccination","slug":"belimumab-plus-late-vaccination","indication":"Other","status":"marketed"},{"name":"Single Dose Group: Belimumab SC 1 x 200 mg","genericName":"Single Dose Group: Belimumab SC 1 x 200 mg","slug":"single-dose-group-belimumab-sc-1-x-200-mg","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"albumin interferon alfa-2b","genericName":"albumin interferon alfa-2b","slug":"albumin-interferon-alfa-2b","indication":"Hepatitis B","status":"phase_3"}]}],"pipeline":[{"name":"Lymphostat B","genericName":"BELIMUMAB","slug":"belimumab","phase":"marketed","mechanism":"Belimumab works by blocking the B Lymphocyte Stimulator, a protein that can contribute to the autoimmune response in Systemic lupus erythematosus.","indications":["Systemic lupus erythematosus"],"catalyst":""},{"name":"Albuferon","genericName":"Albuferon","slug":"albuferon","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Belimumab plus Early Vaccination","genericName":"Belimumab plus Early Vaccination","slug":"belimumab-plus-early-vaccination","phase":"marketed","mechanism":"Belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cells, combined with early vaccination to enhance immune response.","indications":["Systemic lupus erythematosus (SLE) with early vaccination strategy"],"catalyst":""},{"name":"Belimumab plus Late Vaccination","genericName":"Belimumab plus Late Vaccination","slug":"belimumab-plus-late-vaccination","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Single Dose Group: Belimumab SC 1 x 200 mg","genericName":"Single Dose Group: Belimumab SC 1 x 200 mg","slug":"single-dose-group-belimumab-sc-1-x-200-mg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"albumin interferon alfa-2b","genericName":"albumin interferon alfa-2b","slug":"albumin-interferon-alfa-2b","phase":"phase_3","mechanism":"Albumin interferon alfa-2b is a recombinant form of interferon alfa-2b fused to human albumin, which is used to enhance its half-life and therapeutic effects.","indications":["Hepatitis B"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNRHpTbU9hOUFsaWJ4ZExJSVh1Y09IQ3pheVlCM0N6M21iLWJ0THl5SUFuTkpSLU9TMm9WVTFMdFl4TloteFFVWjBHTHR5N3BoMVUyT1YzNTBqdzQ4Yl81TElVWVNXQ1JkSV9YcXVtYmxzX1l1Rlh1Z1NIZFZyWlZBRVh2RTFFNkxZdWxDVnB5bDBmSWxQa25lUlIzdw?oc=5","date":"2026-01-08","type":"pipeline","source":"Cleanroom Technology","summary":"Samsung Biologics enters US biopharma manufacturing market with $280m GSK acquisition - Cleanroom Technology","headline":"Samsung Biologics enters US biopharma manufacturing market with $280m GSK acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPODcwaEFOV1ZRRmNSSWliUGRlVkJEQVVMZnJPTm1ZM19kZi1ES095NDdzbUk3SERyQ01fcWVBckJTTk1XMTIyTEV5bEdZLWRyMUw0TzcweUktMmxrcWs0NURja1ZJa0tpeFFRUkwwamZ5emJFRmZkZDJzdU43RmM1X2IxdUtwOHVVRjZrWTFub0pkblU2VzV5MU85dm9oVlpGVmVTTWNXcTFQNkdoRERlOFBmYk0wOWxhX1h1MjFfeW4?oc=5","date":"2026-01-05","type":"deal","source":"European Pharmaceutical Review","summary":"Samsung gains first US manufacturing site through $280m GSK deal - European Pharmaceutical Review","headline":"Samsung gains first US manufacturing site through $280m GSK deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOanBmOERSNEo3Vll6WXNad1RENzF2VVJaLVF0WFE4Z1F4VWluSklaS2hqbWlSc3BJaVR0R0wwMWd3cXNEckdsd0NXV3JBbUxpQlBndkw3MjVNUFRUZ3FSU1owQ2VadE5LYkd3Z1pHeTM3d3pfTV9BN1BLUFlFS09zSGJhck16T2x0MDZPYmU0cDc?oc=5","date":"2025-12-23","type":"deal","source":"Pharmaceutical Technology","summary":"Samsung Biologics to acquire Human Genome Sciences - Pharmaceutical Technology","headline":"Samsung Biologics to acquire Human Genome Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNRThqaTZNU0hSZFNDUUVwUEFOaDZtM1JVNDBSX0pLb1VaRV96Ym5SeUxGUzhVYjQtZUp6WU5hdko3VEtKLXRzTEl4SFMzRlRrZ1hMd2ltTmpoc210U1hkREthLTJWNTZpekI4YzdoVy03d21oWTlLcmpseHdlclFSMDZRM20yUlg2cmd6d2FINEN3N2NRZmxSc2gtUU5mbFhSVHROa25B?oc=5","date":"2025-12-22","type":"deal","source":"Contract Pharma","summary":"Samsung Biologics Acquires Human Genome Sciences from GSK - Contract Pharma","headline":"Samsung Biologics Acquires Human Genome Sciences from GSK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWk53aEh6RkhxWmZXMTQ5WVpnNk41UjA1YVFsVVhhRkxycWIzTXIwWUNwem82X19URWN2NTd0REJ3V1oxNVI2cEZHWWhDUll1bC03amFaaGtOOG9qR3pjZTR1UGFFMGZoU3hxV19wTUotUlVIY1l0Rjgtem5ZWGNyLTlJaVJKNU42ZDJpcVdJLS1JcllUOTRheWZlelctSFRyb1ZKSmszZGxocElsTnc?oc=5","date":"2025-12-22","type":"pipeline","source":"Fierce Pharma","summary":"Samsung Biologics pays GSK $280M to secure first US manufacturing site - Fierce Pharma","headline":"Samsung Biologics pays GSK $280M to secure first US manufacturing site","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPX3lBZ3VRbDhwYlhuM2lvaEhlWE1yQ3pyZ3Z4bXJvcjZ4ckRQU2JSZjViby1pQ1l5d2puVDZZVzFKWEpZTGZkN0dNUVN0d0x3YWhxR1ZRc3dBeUNmUWZKNlNRZWdHT3NRd3oybDZwOUQtVzJPN0w4MXZ2OTM0TC1McF9jZ2IxWHkzUmdRcjFMMXFOY214d1RHbUt5dHBzNUN6QUo0LXVQMmkxTmNWQmUzOUNnTQ?oc=5","date":"2025-12-22","type":"pipeline","source":"Pharmaceutical Commerce","summary":"Samsung Biologics Enters US Manufacturing Market with $280M GSK Site Acquisition - Pharmaceutical Commerce","headline":"Samsung Biologics Enters US Manufacturing Market with $280M GSK Site Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9qNy1UNS1rXzh3dUw2aFFTQWRoSC1FRnZoXzRqNDRrNU0xdEdCVzJ5VGpITVpOY2VVOWdYYm5BaHVJWU9jcXFRUk9NZzVxb2Fza0ptdWRWd09jS3dwYU1Mb0c0dllHNDMwUnFWdmxn?oc=5","date":"2025-12-22","type":"deal","source":"KED Global","summary":"Samsung Biologics to buy its first US drug factory from GSK for $280 mn - KED Global","headline":"Samsung Biologics to buy its first US drug factory from GSK for $280 mn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5xNkk1dk5uSzlUYlRkeGRPNlNKYWhIVFZJQ01iXzJzbzFrU2EyUlY2U0MwODBjdEFrV2NhcFR4VWRqMW51ZE9FUkxMZmxZSjM3bF95dFFMVVdhUk9nS0Q1Q21HbE80a0nSAWxBVV95cUxOYWhqSlhiLTM0YWFpcko1RkRLT0JqRmRzaUdUS2JteHJBZnh1d3BqOUNETlA4Zl9USHNfc0tzUUN0TzczOGw5Y1hweDVsM0pQcG5fc3BSSGZNemdUZXBHaFpYTUhIcGtBRzFwakI?oc=5","date":"2025-12-22","type":"pipeline","source":"Trend Hunter","summary":"Inaugural US-Based Manufacturing Sites - Trend Hunter","headline":"Inaugural US-Based Manufacturing Sites","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYTZFSFk3U3lodGdVM1dRRUFCSHBnSDJTXzFCX3didkhrV21CcXV2S1B5TnIwWUVHUE12T1M5VmhLR0p3VWNpR3lwcEc2VW5PYWhST2h4NFk5Z19OV0RBRGt1ZXNSMWlfRFJZclNJTWVmVEFSWkFMUGNUUGdTX0tJN3h3YzhaMC1BZ0EzcTdvem1XSkliRXlwWkV5UkVubldCbzBHZHpVRm9sSGhMZmh2Si1rOUFSeVl3Tkc00gHAAUFVX3lxTE9Jd0p2alZ1eVpRaE9IS1QwT0l1ZEN6bVhXcFdmbVpSeVN5V1lSM2xINGtSVF9KNDhKeGdWMTdZNXN0U0IyYkNPUW5jMWFPMk1lZ1JXTzdXRFpudTh1Mi05dDYxNkdnSFJqMUUzd0k2RWUzTm5iUUx0R0o4bi1YcDVvc0pEZ1NiQmVwRXZXdllHVUdicF9SdVhyYVhTUEQ3dXpKS3JmcG1mUmw2X3FZQ1Bvd3Bndjd0MmgzcUh1Q2xwag?oc=5","date":"2025-12-22","type":"pipeline","source":"The Korea Times","summary":"Samsung Biologics takes over bio plant in Maryland from GSK - The Korea Times","headline":"Samsung Biologics takes over bio plant in Maryland from GSK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPVmZuRTlZbzdmR2JOSE5hS2haSlJJak1rTTRZa3FWYS12UVcyRS1hRWdLV0pHTEtyaHpzSUZEaWFoQ19hbGt0UXEyQjlEZVFQOUprR01BR2xudm5nQmxYRGRlRlJHYTFiSFFscEpMR0d5cjBWWTJ4Tl9qSG5qQTg2RHFEZ2tMWU1WQVdaTng4R2dUNE0xZHFlRy15UGtWWTNuTVVaYjlrOWNPQ1k0aUwzUERuZ2c1WDFQVm5SS1pXNmtBOXZkdUVNeVpCTm5rUGRrMkx6NDJFalpsUXdSNjlPQWwwTEZtbDlTaWg2ZE0xdXhaNGhTbDJNZ1NkLXlPbWZyU0E?oc=5","date":"2025-12-21","type":"pipeline","source":"PR Newswire","summary":"Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK - PR Newswire","headline":"Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQVm5mdUY1c09oZDRveTJMcmdXS1JyakM1dWYzMjFZLThZbVlFS3Z5NkxXTjFCRGdhdWJIR1Z5OWNmaXV1V1Nhck1EcE9fZ193RUhKTzg5VlM1WjdXRDVfNS1OUTlhUldXVDJ6dVBINHV2SHRLZkIwWVBOSVVNRDdEUGtJY0x6R2gtRFdfSmhHbjFDeHhteXdYSDk0dzE3RW1tRDc0UkxJcU5MOG5CNGlPLXpjX2ZkelV4YWt0bjNPbHV6TXNJcFZjWlFBOWdxZw?oc=5","date":"2025-12-21","type":"deal","source":"reuters.com","summary":"Samsung Biologics to buy US drug production facility from GSK for $280 million - reuters.com","headline":"Samsung Biologics to buy US drug production facility from GSK for $280 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQWEJQeGh1cFNuTTBqdS1acUNwQXhGaGdfWGhfRHdMOUpvRURJZjdIY0pKQlZaUTJJbkRtZ0FXWlZkRVZHQVRwN0JManFDaktxWVROcWZPdXJxSnFLd29MOG1kWWZTVWh4aVN3NlBTQUxQcTdoeDRJMzhzalkwWjNLcVJidGJ1SzZZX05FYUJ0VmdiNC1Vd3FlNUlnNTJtZWJjNEdONkd5M1RHVjFtSDg4X01NRWdQdw?oc=5","date":"2025-12-21","type":"pipeline","source":"Stock Titan","summary":"Samsung Biologics snaps up Maryland drug plant, its first in the US - Stock Titan","headline":"Samsung Biologics snaps up Maryland drug plant, its first in the US","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"marketed":3,"phase_2":1,"phase_1":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}